=Pluristem Therapeutics (PSTI) : femoral neck fracture trial

Pluristem Therapeutics is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. Wikipedia

• Stock: PSTI (NASDAQ) 
• Headquarters: Haifa, Israel
• Founder: Shai Meretzki
• Founded: May 11, 2001
• pluristem.com

Pluristem Therapeutics announces that its Phase III study of PLX-PAD cells to support recovery following surgery for femoral neck fracture has been awarded an $8.7 million non-dilutive grant from the Horizon 2020 program
The Phase III trial of PLX-PAD cells in the treatment of femoral neck fracture will be a collaborative effort between Pluristem and an international consortium led by the Charit -- Universittsmedizin Berlin, under the leadership of Dr. Tobias Winkler, Principal Investigator at the Berlin-Brandenburg Center for Regenerative Therapies, Julius Wolff Institute and Center for Musculoskeletal Surgery.